IQVIA (IQV): financials, SEC filings and peers

IQVIA (IQV) is a life sciences tools & services company in the Health Care sector of the S&P 500, headquartered in Durham, North Carolina.

It was founded in 1982 and joined the S&P 500 on August 29, 2017.

Its fiscal year ends in December, and its shares trade on the NYSE.

In its SEC filings it is classified as “Services-Commercial Physical & Biological Research”.

IQVIA at a glance

Revenue (12 months): $16.6B
Revenue growth: +7.3%
Operating margin: 13.2%
Net income (12 months): $1.4B
Free cash flow (12 months): $2.1B
Cash: $1.9B
Debt: $15.8B
Diluted EPS (12 months): $8.06

Twelve months to March 31, 2026, from the 10-Q filed May 5, 2026.

Latest twelve months

Over the twelve months to March 31, 2026, IQVIA reported revenue of $16.6 billion, about the same as a year earlier (+7.3%).

Its operating margin was 13.2%: for every $100 of sales, about $13 was left as operating profit.

Net income was $1.4 billion (8.3% of revenue), 3.8% higher than a year earlier.

Operating cash flow was $2.7 billion and capital spending $588 million, leaving free cash flow of $2.1 billion (12.7% of revenue).

At the end of the period it held $1.9 billion in cash and $15.8 billion in debt, a net debt position of $13.9 billion.

The diluted share count fell 4.3% in a year, typically the result of buybacks.

Five-year trend

Revenue went from $11.4 billion in fiscal 2020 to $16.3 billion in fiscal 2025, about 7.5% a year.
Revenue has grown for 5 fiscal years in a row.
Operating margin widened from 6.4% to 13.4% over the same years.
Free cash flow was positive in each of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$13.9B	$14.4B	$15.0B	$15.4B	$16.3B
Revenue growth	22.1%	3.9%	4.0%	2.8%	5.9%
Operating margin	10.0%	12.5%	13.2%	14.3%	13.4%
Net income	$966M	$1.1B	$1.4B	$1.4B	$1.4B
Free cash flow	$2.3B	$1.6B	$1.5B	$2.1B	$2.1B
Diluted EPS	$4.95	$5.72	$7.29	$7.49	$7.84

Fiscal years as reported in IQVIA’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

8-K filed September 23, 2026 — Material agreement; New debt obligation
8-K filed September 9, 2026 — Other event
10-Q filed July 28, 2026 — quarterly report
8-K filed July 28, 2026 — Earnings results
8-K filed June 11, 2026 — Material agreement; New debt obligation
8-K filed June 4, 2026 — Other event
8-K filed June 3, 2026 — Other event
8-K filed May 7, 2026 — Other event

All IQVIA filings on SEC EDGAR

Companies like IQVIA

Other S&P 500 companies in Life Sciences Tools & Services:

More from Health Care

All 60 Health Care companies →

Questions about IQVIA

Is IQVIA's revenue growing?

Yes. Revenue for the twelve months to March 31, 2026 was $16.6 billion, up 7.3% from a year earlier, according to its SEC filings.

Is IQVIA profitable?

Yes. It earned $1.4 billion in net income over the twelve months to March 31, 2026, a net margin of 8.3%.

Does IQVIA have more cash or more debt?

At March 31, 2026 it had $1.9 billion in cash and $15.8 billion in debt, so more debt than cash.

When did IQVIA last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on July 28, 2026.

Which companies are similar to IQVIA?

In the S&P 500, IQVIA is grouped in Life Sciences Tools & Services within the Health Care sector. Agilent Technologies (A), Charles River Laboratories (CRL), Danaher Corporation (DHR), Illumina, Inc. (ILMN), Mettler Toledo (MTD) are in the same group.

Understand the numbers

Source: IQVIA’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.